Maine Attorney General Aaron M. Frey has announced a significant settlement agreement with pharmaceutical company Sanofi-Aventis U.S. LLC, making insulin more affordable for uninsured and commercially insured residents. Under the agreement, Mainers will be able to purchase a monthly supply of Sanofi insulin products for a flat rate of $35 through 2029.
The settlement applies to popular insulin products, including Admelog, Lantus, Toujeo, Apidra, and any biosimilar versions marketed by Sanofi in the U.S.
“Insulin is life-sustaining medication, and far too many Mainers struggle to afford it,” said Attorney General Frey. “My Office will continue to closely monitor drug pricing and take action to protect consumers to ensure access to these essential medications.”
Beyond the reduced pricing, Sanofi has agreed to implement an enrollment message program to assist patients and pharmacists in identifying eligibility for the low-cost insulin option. The system will provide real-time alerts at pharmacy counters across the state, helping eligible individuals take advantage of the program.
Mainers interested in exploring potential savings should speak with their pharmacist when filling prescriptions to determine eligibility.